The number of elderly patients with cancer continues to increase. The optimal chemotherapeutic regimen for inoperable non-small-cell lung cancer (NSCLC) in elderly patients, especially over 80 years old, remains controversial. S-1, a newly developed oral fluorouracil antitumor drug, has been reported to be effective in the treatment of gastrointestinal and pancreatic tumors and/or NSCLC. We experienced a case of an elderly patient with advanced-stage NSCLC who responded well to S-1 monotherapy with tolerable toxicities and has had three years of disease-free survival. S-1 appears to have significant activity with mild toxicities for selected elderly NSCLC patients and in our view warrants further clinical study.
A 43-year-old woman presented with a palpable hard mass in the left breast. Physical examination revealed a 1.0×0.8cm, nontender, and firm ovoid mass. A mammogram revealed a focal asymmetric density in the left breast that was suspected of being a carcinoma. Ultrasonography of the left breast showed a 12.0×7.5×6.5mm, poorly defined hypoechoic mass with irregular margins and posterior acoustic shadowing. Fine-needle aspiration cytology revealed benign cells. We performed a mammotome probe to make a definite diagnosis, which showed tubular carcinoma. The patient underwent breast conservation surgery (Bp + Ax). The histopathologic examination revealed well-differentiated tubular carcinoma. Immunohistochemical staining showed that estrogen receptors and progesterone receptors were positive, while human epidermal growth factor receptor type 2 was negative. After the operation, she received endocrine therapy for 5 years. She is alive without any residual or metastatic disease 90 months after being diagnosed.